Bioethics Ltd financial data

Symbol
BOTH on OTC
Industry
Blank Checks
Location
1661 Lakeview Circle, Ogden, UT
State of incorporation
NV
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.83 % +1470%
Debt-to-equity -101 % -0.78%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.14M shares
Common Stock, Shares, Outstanding 1.14M shares 0%
Entity Public Float 27.4K USD -4.5%
Common Stock, Value, Issued 1.14K USD 0%
Weighted Average Number of Shares Outstanding, Basic 1.14M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
General and Administrative Expense 103K USD +125%
Operating Income (Loss) -103K USD -125%
Nonoperating Income (Expense) -50K USD -4.78%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -153K USD -63.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -53.1K USD -138%
Earnings Per Share, Basic -0.1 USD/shares -25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.2K USD +3451%
Assets, Current 17.2K USD +3451%
Assets 17.2K USD +3451%
Accounts Payable, Current 177K USD +52.1%
Accrued Liabilities, Current 109K USD +21.7%
Liabilities, Current 880K USD +17%
Liabilities 880K USD +17%
Retained Earnings (Accumulated Deficit) -1.41M USD -12.2%
Stockholders' Equity Attributable to Parent -863K USD -14.8%
Liabilities and Equity 17.2K USD +3451%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.9K USD -93.6%
Net Cash Provided by (Used in) Financing Activities 5.85K USD +95%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 1.14M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.2K USD +3451%
Deferred Tax Assets, Valuation Allowance 289K USD +7.44%
Cash and Cash Equivalents, Period Increase (Decrease) -180 USD +10%
Depreciation 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 261K USD +8.3%
Preferred Stock, Shares Issued 620K shares
Preferred Stock, Shares Authorized 25M shares 0%
Additional Paid in Capital 556K USD +11.1%
Preferred Stock, Shares Outstanding 620K shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 50K USD +4.78%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%